Abstract
Pathogens can infect almost all tissues and cause serious infections. Objective was to evaluate efficacy and safety of fixed-dose combination of Ceftriaxone-Vancomycin in patients with various infections. Patients (n=305) suffering from different bacterial infections (serious respiratory tract disease, bronchitis, gastrointestinal tract infections, urinary tract infection, cellulites and meningitis) were enrolled. Patients were randomized into two groups depending on severity of illness. Group A (n=106) and Group B (n=199) patients were given intravenous dose of fixed-dose combination 1.5 g B.D. and 3.0 g B.D. respectively for 3-10 days. Hemoglobin, total leukocyte count, erythrocyte sedimentation rate, urea, creatinine levels serum glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase activities were recorded before and on completion of the treatment. Most of patients (70%) were cured in seven or less than seven days of the treatment. Significant decrease in total leukocyte count, erythrocyte sedimentation rate levels were observed indicating patients were cured from the infections. No significant alterations were observed in hemoglobin, serum urea, creatinine levels, glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase activities on completion of treatment. The fixed-dose combination of Ceftriaxone – Vancomycin, is found to be effective in treating various bacterial infections without any toxic effect on liver and kidney. Patients well tolerated the drug without major adverse effects.
Keywords: Ceftriaxone-vancomycin, efficacy, safety
Current Drug Safety
Title: Efficacy and Safety Study of Fixed-Dose Combination of Ceftriaxone- Vancomycin Injection in Patients with Various Infections
Volume: 3 Issue: 1
Author(s): Sanjay Mohan Shrivastava, Manu Chaudhary and Rajesh Sehgal
Affiliation:
Keywords: Ceftriaxone-vancomycin, efficacy, safety
Abstract: Pathogens can infect almost all tissues and cause serious infections. Objective was to evaluate efficacy and safety of fixed-dose combination of Ceftriaxone-Vancomycin in patients with various infections. Patients (n=305) suffering from different bacterial infections (serious respiratory tract disease, bronchitis, gastrointestinal tract infections, urinary tract infection, cellulites and meningitis) were enrolled. Patients were randomized into two groups depending on severity of illness. Group A (n=106) and Group B (n=199) patients were given intravenous dose of fixed-dose combination 1.5 g B.D. and 3.0 g B.D. respectively for 3-10 days. Hemoglobin, total leukocyte count, erythrocyte sedimentation rate, urea, creatinine levels serum glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase activities were recorded before and on completion of the treatment. Most of patients (70%) were cured in seven or less than seven days of the treatment. Significant decrease in total leukocyte count, erythrocyte sedimentation rate levels were observed indicating patients were cured from the infections. No significant alterations were observed in hemoglobin, serum urea, creatinine levels, glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase activities on completion of treatment. The fixed-dose combination of Ceftriaxone – Vancomycin, is found to be effective in treating various bacterial infections without any toxic effect on liver and kidney. Patients well tolerated the drug without major adverse effects.
Export Options
About this article
Cite this article as:
Shrivastava Mohan Sanjay, Chaudhary Manu and Sehgal Rajesh, Efficacy and Safety Study of Fixed-Dose Combination of Ceftriaxone- Vancomycin Injection in Patients with Various Infections, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783333943
DOI https://dx.doi.org/10.2174/157488608783333943 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Spatial Correlations between the Vacuolation, Prion Protein (PrPsc) Deposits and the Cerebral Blood Vessels in Sporadic Creutzfeldt-Jakob Disease
Current Neurovascular Research Infrequent Infections in COPD
Current Respiratory Medicine Reviews Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Occipital Encephalocele: Cause, Incidence, Neuroimaging and Surgical Management
Current Pediatric Reviews Overview of Congenital Infections: The Prominence of Cytomegalovirus
Infectious Disorders - Drug Targets The Emergence of Quaternary Ammonium Compounds Resistance in Escherichia coli Isolated from Hospitals of Qazvin, Iran
Infectious Disorders - Drug Targets Neonatal Fever in the Term Infant: Evaluation and Management Strategies
Current Pediatric Reviews Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Machine Learning and Tubercular Drug Target Recognition
Current Pharmaceutical Design Clinical Characteristics of Behcet’s Disease in 453 Egyptian Patients Suffering from Uveitis with Gender Comparison
Current Rheumatology Reviews Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends
Current Vascular Pharmacology The Multi-faceted Profile of Corticotropin-releasing Factor (CRF) Family of Neuropeptides and of their Receptors on the Paracrine/Local Regulation of the Inflammatory Response
Current Molecular Pharmacology The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design Effects of the Capsular Polysaccharides of Cryptococcus neoformans on Phagocyte Migration and Inflammatory Mediators [General Articles]
Current Medicinal Chemistry Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Preface
Current Drug Targets - Infectious Disorders The Protein Therapy of Kallikrein in Cerebral Ischemic Reperfusion Injury
Current Medicinal Chemistry